Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?

Claudio Galarza, Diana Valencia, Gabriel J. Tobón, Luis Zurita, Rubén D. Mantilla, Ricardo Pineda-Tamayo, Adriana Rojas-Villarraga, Juan C. Rueda, Juan Manuel Anaya

Research output: Contribution to journalArticlepeer-review

63 Scopus citations

Fingerprint Dive into the research topics of 'Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?'. Together they form a unique fingerprint.

Medicine & Life Sciences